10-Q: Milestone Pharma Reports Q1 2026 Results, CARDAMYST Sales Begin

Milestone Pharmaceuticals Inc. reported its first quarter 2026 financial results, marking the initial product revenue from CARDAMYST and detailing ongoing clinical development for AFib-RVR.

Summary

• Milestone Pharmaceuticals Inc. reported its financial results for the first quarter ended March 31, 2026.
• The company generated its first product revenue of $0.2 million from CARDAMYST (etripamil) nasal spray, which became available in U.S. retail pharmacies in January 2026.
• Research and development expenses decreased by 34.7% to $3.3 million, primarily due to reduced outside service costs for drug development.
• Commercial expenses increased by 52.4% to $15.8 million, reflecting investments in the launch of CARDAMYST.
• The company reported a net loss of $26.1 million for the quarter, compared to a net loss of $20.8 million in the prior year period.
• As of March 31, 2026, Milestone had $71.3 million in cash and cash equivalents and $112.9 million in short-term investments, which management believes is sufficient for at least the next 12 months.
• The company is advancing the Phase 3 registrational program for etripamil nasal spray for Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR), with first patient enrollment expected in the second half of 2026.
• Milestone announced the sale of its Greater China rights for CARDAMYST to Everest Medicines on March 23, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic filing, with the commencement of product revenue being a significant positive, balanced by continued operational losses and the inherent risks of drug development.

Positives

• Generated first product revenue of $0.2 million from CARDAMYST.
• CARDAMYST became available in U.S. retail pharmacies in January 2026.
• Significant increase in cash and short-term investments to $184.2 million, providing a strong liquidity position.
• Advancement of the Phase 3 program for etripamil in AFib-RVR, with enrollment expected in H2 2026.
• Successful sale of Greater China rights for CARDAMYST to Everest Medicines, providing strategic partnership and potential future revenue.

Negatives

• Net loss of $26.1 million for the quarter, indicating continued operational losses.
• Significant increase in commercial expenses by 52.4% to $15.8 million, driven by the CARDAMYST launch.
• The company expects to continue incurring significant losses for the foreseeable future.
• Reliance on external financing for future operations and development.

Risks

• The inherent uncertainty of clinical trial success for etripamil in AFib-RVR and other indications.
• The ability to obtain regulatory approval for etripamil in regions outside the United States.
• Competition in the cardiovascular medicine market.
• The potential for changes in government and third-party payor coverage and reimbursement.
• The company's reliance on a single source manufacturer for key components and finished products.
• The potential impact of macroeconomic factors such as inflation and interest rate changes on operations and financing.
• The dynamic and unpredictable tariff and trade landscape may create substantial uncertainty and planning challenges.

Future Outlook

The company expects to continue incurring significant losses for the foreseeable future, with substantial capital resources focused on the commercialization of CARDAMYST and the development of etripamil for AFib-RVR. Management believes current cash, cash equivalents, and short-term investments are sufficient to fund operations for at least the next 12 months.

Management Comments

• We believe that PSVT is a large and under-recognized market which we estimate affects more than two million Americans.
• We believe that etripamil has the potential to help people experiencing a symptomatic episode of AFib-RVR to self-treat and to conveniently, reliably, and quickly reduce their elevated heart rate.
• We expect our future commercial expenses will increase as we invest in the infrastructure, personnel, and operational expenses required to commercialize CARDAMYST in the United States.
• We expect to continue to incur significant losses for the foreseeable future.

Industry Context

StockSavvy.ai notes that Milestone Pharmaceuticals is navigating the highly competitive biopharmaceutical landscape with a focus on cardiovascular treatments. The recent FDA approval of CARDAMYST and the ongoing development of etripamil for AFib-RVR position the company to address significant unmet needs in the market, though it faces the typical challenges of drug commercialization and clinical development.

Comparison to Industry Standards

• The market for PSVT treatment is characterized by a lack of recent pharmaceutical innovation, with current treatments largely relying on intravenous administration in emergency settings. Milestone's CARDAMYST offers a self-administered alternative, a significant differentiator.
• The AFib-RVR market is also characterized by a need for faster and more reliable patient-administered treatments, as current oral options have delayed onset of action. Etripamil's potential to bridge this gap aligns with industry trends towards patient-centered care and reduced emergency department utilization.
• The company's R&D expenses as a percentage of revenue are typical for a biopharmaceutical company in the development and early commercialization phase, reflecting significant investment in pipeline advancement.

Legal Proceedings

• The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding that could have an adverse effect on its business, operating results, or financial condition.

Stakeholder Impact

• Shareholders: Dilution risk from potential future equity financings; potential for long-term value creation if CARDAMYST and etripamil are successful.
• Employees: Continued employment opportunities with a growing commercial team and R&D efforts; potential for stock-based compensation.
• Customers (Wholesalers/Pharmacies): Opportunity to stock and distribute a new cardiovascular medication.
• Payors: Potential for cost savings if CARDAMYST reduces emergency department visits and hospitalizations for PSVT.
• Suppliers: Continued demand for manufacturing and clinical trial services.

Next Steps

• Continue commercialization of CARDAMYST in the United States.
• Enroll the first patient in the Phase 3 registrational program for etripamil for AFib-RVR in the second half of 2026.
• Seek marketing approval for etripamil nasal spray in regions outside the United States through partners.
• Continue to invest in sales, marketing, and manufacturing capabilities.
• Initiate preclinical studies and clinical trials for etripamil for additional indications or new product candidates.
• File for an ATM Offering under the new Sales Agreement.

Key Dates

Recommendation

The company has achieved a significant milestone with the commencement of product revenue from CARDAMYST, which is a positive development. However, the substantial net loss, ongoing need for significant R&D investment, and reliance on future financing and clinical success for the AFib-RVR indication warrant a cautious approach. The current valuation should reflect these factors, making 'hold' appropriate until further clarity on commercial traction and clinical development progress emerges.

Keywords

Milestone Pharmaceuticals, CARDAMYST, etripamil, PSVT, AFib-RVR, nasal spray, FDA approval, biopharmaceutical, clinical trials, revenue, net loss